Browsing Tag
rare kidney disease
2 posts
How the VALIANT Phase 3 data may strengthen EMPAVELI’s nephrology market position
Find out how Sobi’s VALIANT Phase 3 data may reshape EMPAVELI’s nephrology market position and what it means for rare kidney disease growth.
Q32 Bio divests complement inhibitor ADX-097 as Akebia Therapeutics builds rare kidney disease pipeline
Discover how Q32 Bio’s ADX-097 sale to Akebia Therapeutics reshapes both companies’ pipelines, balance sheets, and investor outlook.